Printer Friendly

Mylan introduces Ibandronate Sodium Injection.

M2 EQUITYBITES-September 9, 2014-Mylan introduces Ibandronate Sodium Injection

(C)2014 M2 COMMUNICATIONS http://www.m2.com

It was reported yesterday that Mylan, a global generic and specialty pharmaceuticals company, has launched Ibandronate Sodium Injection, one mg (base)/mL, packaged in three mg (base)/three mL pre-filled glass syringes.

The product is a generic version of Hoffmann-La Roche's Boniva Injection.

The company has received approval from the United States Food and Drug Administration for its abbreviated new drug application for this product, which is indicated to treat osteoporosis in postmenopausal women. According to IMS Health, Ibandronate Sodium Injection, one mg (base)/mL, packaged in three mg (base)/ three mL pre-filled glass syringes had US sales of about USD18.4m for the 12 months ending 30 June 2014.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 9, 2014
Words:137
Previous Article:Breckenridge Pharmaceutica files ANDA with Paragraph IV certification for Everolimus.
Next Article:SES GS to provide satellite capacity for US Army network.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters